MYCN and neuroblastoma: When comparing patients by other parameters, the cfDNA levels were also 9‐13 times greater in the high‐risk NB patients compared to the low‐risk NB patients, including patients with >3 metastatic organ locations compared to those with <3 metastatic organs (1647.3 vs 131.3 ng/mL), patients with MYCN amplification compared to those with nonamplification (1387 vs 411.6 ng/mL) and patients with NSE level = 370 ng/mL compared to those with NSE < 370 ng/mL (1165 vs 189.2 ng/mL).